Apoptotic and autophagic cell death induced in cervical cancer cells by a dual specific oncolytic adenovirus

Objective Oncolytic adenoviruses are capable of exerting anticancer effects via a variety of mechanisms, including apoptosis and autophagy. In the present study, the dual-specific antitumor oncolytic adenovirus, Ad-Apoptin-hTERT-E1a (ATV), was used to infect cervical cancer cell lines to test its antitumor effects. Methods To explore the use of apoptin in tumor gene therapy, a recombinant adenovirus ATV expressing the apoptin protein was assessed to determine its lethal and growth-inhibitory effects on human cervical cancer cell line (HeLa) cells in vitro. Nonapoptotic autophagy of HeLa cells infected with ATV was assessed by examining the cell morphology, development of acidic vesicular organelles and the conversion of microtubule-associated protein 1 light chain 3 (LC3) from its cytoplasmic to autophagosomal membrane form. Using gene silencing (knockdown of LC3 and Belin-1), autophagy-associated molecules (e.g. ATG5, ATG12 and ULK1) were monitored by real-time PCR and western blot. Results A series of experiments demonstrated that ATV could significantly induce apoptosis and autophagy in cervical cancer cells, and provided evidence that ATV not only induced apoptosis but also autophagy and ATG5, ATG12 and ULK1 related pathways were not entirely dependent on LC3 and Beclin-1. Conclusion These results indicate that ATV may have a potential application in tumor gene therapy.

[1]  A. Thorburn,et al.  Mechanistic insight into the regulation of SQSTM1/p62 , 2019, Autophagy.

[2]  A. Benito,et al.  Apoptin, A Versatile Protein with Selective Antitumor Activity. , 2018, Current medicinal chemistry.

[3]  A. Almasan,et al.  Autophagy as a mechanism of Apo2L/TRAIL resistance , 2018, Cancer biology & therapy.

[4]  B. Nelson,et al.  Oncolytic viruses as engineering platforms for combination immunotherapy , 2018, Nature Reviews Cancer.

[5]  B. Nelson,et al.  Publisher Correction: Oncolytic viruses as engineering platforms for combination immunotherapy , 2018, Nature Reviews Cancer.

[6]  C. Cui,et al.  PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro , 2018, Cancer biology & therapy.

[7]  K. Lundstrom New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy , 2018, Biologics : targets & therapy.

[8]  J. Esplugues,et al.  Role of p62/SQSTM1 beyond autophagy: a lesson learned from drug‐induced toxicity in vitro , 2018, British journal of pharmacology.

[9]  S. Tooze,et al.  A molecular perspective of mammalian autophagosome biogenesis , 2018, The Journal of Biological Chemistry.

[10]  Lucy F. Stead,et al.  Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade , 2018, Science Translational Medicine.

[11]  T. Lamark,et al.  Regulation of selective autophagy: the p62/SQSTM1 paradigm. , 2017, Essays in biochemistry.

[12]  G. Swarup,et al.  Optineurin promotes autophagosome formation by recruiting the autophagy-related Atg12-5-16L1 complex to phagophores containing the Wipi2 protein , 2017, The Journal of Biological Chemistry.

[13]  A. Thorburn,et al.  Targeting autophagy in cancer , 2017, Nature Reviews Cancer.

[14]  S. Nakano,et al.  The role of p62/SQSTM1 in sporadic inclusion body myositis , 2017, Neuromuscular Disorders.

[15]  Yung-Hyun Choi,et al.  Induction of apoptosis by ethanol extract of Evodia rutaecarpa in HeLa human cervical cancer cells via activation of AMP-activated protein kinase. , 2016, Bioscience trends.

[16]  H. Kaufman,et al.  Erratum: Oncolytic viruses: a new class of immunotherapy drugs , 2016, Nature Reviews Drug Discovery.

[17]  J. G. Teodoro,et al.  Activation of the Chicken Anemia Virus Apoptin Protein by Chk1/2 Phosphorylation Is Required for Apoptotic Activity and Efficient Viral Replication , 2016, Journal of Virology.

[18]  A. Bishayee,et al.  Molecular targets of curcumin for cancer therapy: an updated review , 2016, Tumor Biology.

[19]  L. Aurelian Oncolytic viruses as immunotherapy: progress and remaining challenges , 2016, OncoTargets and therapy.

[20]  Kai Xu,et al.  shRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapy , 2016, Oncotarget.

[21]  H. Kaufman,et al.  Oncolytic viruses: a new class of immunotherapy drugs , 2016, Nature Reviews Drug Discovery.

[22]  H. Kaufman,et al.  Oncolytic viruses: a new class of immunotherapy drugs , 2015, Nature Reviews Drug Discovery.

[23]  Mark A. Kay,et al.  Drugging RNAi , 2015, Science.

[24]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[25]  Guohua Yang,et al.  Antitumor effects of a dual cancer-specific oncolytic adenovirus on colorectal cancer in vitro and in vivo , 2014, Experimental and therapeutic medicine.

[26]  T. Fujiwara,et al.  Abstract 342: Telomerase-dependent oncolytic adenovirus sensitizes human osteosarcoma cells to chemotherapy through Mcl-1 downregulation , 2014 .

[27]  U. Dietrich,et al.  Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency. , 2014, Cancer research.

[28]  A. Choi,et al.  Interaction of caveolin-1 with ATG12-ATG5 system suppresses autophagy in lung epithelial cells. , 2014, American journal of physiology. Lung cellular and molecular physiology.

[29]  T. DeWeese,et al.  Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer. , 2014, International journal of radiation oncology, biology, physics.

[30]  Lili Sun,et al.  Anti-Tumor Effects of an Oncolytic Adenovirus Expressing Hemagglutinin-Neuraminidase of Newcastle Disease Virus in Vitro and in Vivo , 2014, Viruses.

[31]  Xiao Li,et al.  Therapeutic efficacy of an hTERT promoter-driven oncolytic adenovirus that expresses apoptin in gastric carcinoma. , 2012, International journal of molecular medicine.

[32]  Jin Ningyi,et al.  Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo , 2010, Molecular Cancer.

[33]  S. Bär,et al.  Viral proteins killing tumor cells: New weapons in the fight against cancer , 2008, Cancer biology & therapy.

[34]  C Milligan,et al.  Screening for cervical cancer. , 1975, The American journal of nursing.

[35]  L. Van Le,et al.  A Review of Gynecologic Oncology in the Global Setting: Educating and Training the Next Generation of Women's Health Providers. , 2019, Obstetrical & gynecological survey.

[36]  T. Panaretakis,et al.  Dynamics of Atg5-Atg12-Atg16L1 Aggregation and Deaggregation. , 2017, Methods in enzymology.

[37]  M. Noteborn,et al.  Apoptin towards safe and efficient anticancer therapies. , 2014, Advances in experimental medicine and biology.

[38]  M. Tavassoli,et al.  Signalling of Apoptin. , 2014, Advances in experimental medicine and biology.